


CLAIMS

What is claimed is:

1. A compound, including enantiomers, stereoisomers, rotomers and tautomers of said compound, and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in Formula I:

**Formula I**

or a pharmaceutically acceptable derivative thereof, where X is: COCH(R⁴)NHCO-CH(R⁵)NHCOCH(R⁶)NHCORⁿ or COCH(R⁴)NHCOCH(R⁵)NHCOCH(R⁶)-NHSO₂R²⁰;

U¹ is a nitrogen atom and U is -CH-;

Z is: NH-CH(R¹)CONHCH(R²)CONHCH(R³)CONHCH(R⁴)CONHCH(R⁵)COR^c; R¹, R², R²², R³, R⁴, R⁵, R⁶, Rⁿ, R², R³, R⁴, R⁵, R¹, R²⁰, and R^c are selected from (a) and (b) as follows:

(a) R¹ is selected from (i)-(v) as follows:

- (i) C₁₋₂ alkyl substituted with Q;
- (ii) C₃₋₁₀ alkyl that is unsubstituted or substituted with Q;
- (iii) cycloalkyl that is unsubstituted or substituted with Q;
- (iv) alkenyl that is unsubstituted or substituted with Q; or
- (v) alkynyl that is unsubstituted or substituted with Q;

R² and R²² are selected from (i) or (ii) as follows:

- (i) R² and R²² together form alkylene, alkenylene, thiaalkylene, thiaalkenylene, alkylenethiaalkylene,

alkyleneazaalkylene, arylene, alkylenearylene or dialkylenearylene; or

(ii) R^2 and R^{22} are each independently selected from H, alkyl, cycloalkyl, aralkyl and heteroaralkyl;

R^3 is selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl;

R^4 is alkyl, cycloalkyl, heteroaralkyl or aralkyl;

R^5 is alkyl or cycloalkyl;

R^6 is alkyl or cycloalkyl;

R^n is alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, aralkenyl, aralkynyl, aryloxy, aralkoxy, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, heteroaryloxy, heteroaralkoxy or $NR^{30}R^{31}$;

R^{30} and R^{31} are each independently selected from the group consisting of H, alkyl, aryl, heteroaryl, aralkyl and heteroaralkyl;

$R^{2'}$ is H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl;

$R^{3'}$ is selected from the group consisting of alkyl, cycloalkyl, aralkyl and heteroaralkyl;

$R^{4'}$ is aralkyl or heteroaralkyl;

$R^{5'}$ is alkyl or cycloalkyl;

$R^{1'}$ is selected from H, alkyl, cycloalkyl, aralkyl and heteroaralkyl;

R^{20} is alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl or heteroaralkynyl;

R^c is selected from amino, hydroxy, alkoxy, cycloalkoxy, alkylamino, alkenyloxy, alkenylamino, aryloxy, heteroaryloxy, arylamino, heteroarylamino, aralkoxy, heteroaralkoxy, aralkylamino and heteroaralkylamino;

Q is halide, pseudohalide, hydroxy, nitrile, formyl, mercapto, alkyl, haloalkyl, polyhaloalkyl, alkenyl containing 1 double bond, alkynyl containing 1 triple bond, cycloalkyl, cycloalkylalkyl, alkylidene, alkylcarbonyl, alkoxy, perfluoroalkoxy, alkylcarbonyloxy or alkylthio; and

(b) R^1 and R^3 , and/or R^2 and R^4 , and/or R^3 and R^5 , and/or R^4 and R^6 , and/or R^1 and R^2 , and/or R^1 and R^3 , and/or R^2 and R^4 , and/or R^3 and R^5 , and/or R^2 and R^1 , and/or R^1 and R^1 together form alkylene, alkenylene, alkylenearylene, dialkylenearylene, alkylene-OC(O)-alkylene, alkylene-NHC(O)-alkylene, alkylene-O-alkylene, alkylene-NHC(O)-alkylene-NHC(O)-alkylene, alkylene-C(O)NH-alkylene-NHC(O)-alkylene, alkylene-NHC(O)-alkylene-C(O)NH-alkylene, alkylene-S(O)_m-S(O)_m-alkylene or alkylene-S(O)_m-alkylene where m is 0-2, and the alkylene and arylene portions are unsubstituted or substituted with Q^1 ; and the others are chosen as in (a).

2. The compound of claim 1, wherein Z is:

$NH-CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONHCH(R^5)COR^6$;

and R^1 is selected from (i)-(iv) as follows:

- (i) C_{1-2} alkyl that is substituted with Q;
- (ii) C_{3-10} alkyl that is unsubstituted or substituted with Q;
- (iii) alkenyl that is unsubstituted or substituted with Q; or
- (iv) alkynyl that is unsubstituted or substituted with Q;

R^2 and R^{22} are selected from (i) or (ii) as follows:

- (i) R^2 and R^{22} together form alkylene, thiaalkylene, or dialkylenearylene; or
- (ii) R^2 and R^{22} are each independently selected from H, alkyl and aralkyl;

R^3 is selected from the group consisting of alkyl, cycloalkyl, aryl and aralkyl;

R^4 is alkyl, heteroaralkyl or aralkyl;

R^5 is alkyl;

R^6 is alkyl;

R^n is alkyl, hydroxycarbonylalkyl, alkoxy, heteroaryl, aryl or aralkyl;

R^2 is H, alkyl, cycloalkyl, aryl or aralkyl;

R^3 is selected from the group consisting of alkyl and heteroaralkyl;

R^4 is aralkyl;

R^5 is alkyl;

R^{1'} is selected from H, alkyl and aralkyl;

R²⁰ is alkyl, aryl, aralkyl or aralkenyl;

R^c is selected from amino, hydroxy, alkoxy, alkenyloxy, alkylamino, alkenylamino and aralkylamino;

Q is halide, pseudohalide, hydroxy, nitrile, formyl, mercapto, alkyl, haloalkyl, polyhaloalkyl, alkenyl containing 1 double bond, alkynyl containing 1 triple bond, cycloalkyl, cycloalkylalkyl, alkylidene, alkylcarbonyl, alkoxy, perfluoroalkoxy, alkylcarbonyloxy or alkylthio; and

R², R²², R³, R⁴, R⁵, R⁶, Rⁿ, R^{2'}, R^{3'}, R^{4'}, R^{5'}, R^{1'}, R²⁰, and R^c are unsubstituted or substituted with one or more substituents each independently selected from Q¹, where Q¹ is halide, pseudohalide, hydroxy, oxo, thia, nitrile, nitro, formyl, mercapto, hydroxycarbonyl, hydroxycarbonylalkyl, alkyl, haloalkyl, polyhaloalkyl, aminoalkyl, diaminoalkyl, alkenyl containing 1 to 2 double bonds, alkynyl containing 1 to 2 triple bonds, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, aralkyl, aralkenyl, aralkynyl, heteroarylalkyl, trialkylsilyl, dialkylarylsilyl, alkyl diarylsilyl, triarylsilyl, alkylidene, arylalkylidene, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryloxy carbonyl, aryloxy carbonylalkyl, aralkoxycarbonyl, aralkoxycarbonylalkyl, arylcarbonylalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, diarylaminocarbonyl, arylalkylaminocarbonyl, alkoxy, aryloxy, perfluoroalkoxy, alkenyloxy, alkynyloxy, aralkoxy, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, aralkoxycarbonyloxy, ureido, alkylureido, arylureido, amino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, arylaminoalkyl, diarylaminoalkyl, alkylaryl aminoalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylaryl amino, alkylcarbonylamino, alkoxycarbonylamino, aralkoxycarbonylamino, arylcarbonylamino, arylcarbonylaminoalkyl, aryloxy carbonylaminoalkyl, aryloxyaryl carbonylamino, aryloxy carbonylamino, alkylsulfonylamino, arylsulfonylamino, azido, dialkylphosphonyl, alkylarylphosphonyl, diarylphosphonyl, alkylthio, arylthio, perfluoroalkylthio, hydroxycarbonylalkylthio,

thiocyano, isothiocyano, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, diarylaminosulfonyl or alkylarylaminosulfonyl; and

the aryl and heteroaryl groups of Q¹ are unsubstituted or substituted with one or more substituents each independently selected from Q², where Q² is alkyl, halide, pseudohalide, alkoxy, aryloxy or alkylenedioxy.

3. The compound of claim 2, wherein:

R¹ is C₃₋₁₀ alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R² and R²² are selected from (i) or (ii) as follows:

(i) R² and R²² together form propylene, butylene or 1,2-dimethylenephenylene, where the butylene and 1,2-dimethylenephenylene groups are unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxycarbonylaminomethyl, phenoxy-carbonylaminomethyl, iso-butoxycarbonylamino, hydroxycarbonylmethyl, hydroxycarbonylmethoxy, 2-propen-1-yl, N-(4-methoxyphenyl)ureido, 3-phenoxybenzoylamino, 4-methoxyphenylmethyl, 9-fluorenylmethoxycarbonylamino, benzyl, 4-methoxybenzoylamino, benzoylamino, 3,4-methylenedioxybenzoylamino, 4-fluorobenzoylamino, phenylsulfonylamino, 4-phenoxybenzoylamino or amino; or

(ii) R² is selected from CH₂SO₂Me, CH₂SCH₂COOH, CH₂CH₂COOH and CH₂SMe; and R²² is H; and R³ is i-Pr, cyclohexyl or 1-methyl-1-propyl.

4. The compound of claim 2, wherein:

R¹ is C₃₋₁₀ alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R² and R²² are selected from (i) or (ii) as follows:

(i) R^2 and R^{22} together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxycarbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxycarbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; or

(ii) R^2 is selected from $\text{CH}_2\text{SO}_2\text{Me}$ and $\text{CH}_2\text{SCH}_2\text{COOH}$; and R^{22} is H; and R^3 is i-Pr, cyclohexyl or 1-methyl-1-propyl.

5. The compound of claim 2, wherein:

R^1 is unsubstituted C_{3-10} alkyl;

R^2 and R^{22} together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxycarbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxycarbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; and

R^3 is i-Pr, cyclohexyl or 1-methyl-1-propyl.

6. The compound of claim 6, wherein R^1 is n-Pr; and R^2 and R^{22} together form unsubstituted propylene.

7. The compound of claim 1, wherein X is:

$\text{COCH}(R^4)\text{NHCOCH}(R^5)\text{NHCOCH}(R^6)\text{NHCOR}^n$.

8. The compound of claim 7, wherein:

R^1 is C_{3-10} alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R^2 and R^{22} are selected from (i) or (ii) as follows:

(i) R^2 and R^{22} together form propylene, butylene or 1,2-dimethylenephenylene, where the butylene and 1,2-dimethylenephenylene groups are unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl, hydroxycarbonylmethoxy, 2-propen-1-yl, N-(4-methoxyphenyl)ureido, 3-phenoxybenzoylamino, 4-methoxyphenylmethyl, 9-fluorenylmethoxycarbonylamino, benzyl, 4-methoxybenzoylamino, benzoylamino, 3,4-methylenedioxybenzoylamino, 4-fluorobenzoylamino, phenylsulfonylamino, 4-phenoxybenzoylamino or amino; or

(ii) R^2 is selected from $\text{CH}_2\text{SO}_2\text{Me}$, $\text{CH}_2\text{SCH}_2\text{COOH}$, $\text{CH}_2\text{CH}_2\text{COOH}$ and CH_2SMe ; and R^{22} is H; and R^3 is i-Pr, cyclohexyl or 1-methyl-1-propyl.

9. The compound of claim 7, wherein:

R^1 is C_{3-10} alkyl, or is alkenyl or alkynyl, and is unsubstituted or substituted with Q;

R^2 and R^{22} are selected from (i) or (ii) as follows:

(i) R^2 and R^{22} together form propylene or 1,2-dimethylenephenylene, where the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenylureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phenoxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenylmethoxy-carbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-carbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; or

(ii) R^2 is selected from $\text{CH}_2\text{SO}_2\text{Me}$ and $\text{CH}_2\text{SCH}_2\text{COOH}$; and R^{22} is H; and

R³ is i-Pr, cyclohexyl or 1-methyl-1-propyl.

10. The compound of claim 9, wherein:

R¹ is unsubstituted C₃₋₁₀ alkyl;

R² and R²² together form propylene or 1,2-dimethylenephenylene, where
the 1,2-dimethylenephenylene group is unsubstituted and the propylene group is
unsubstituted or is substituted with 4-methoxyphenylsulfonylamino, N-phenyl-
ureidomethyl, methyl, benzoylaminomethyl, phenyl, 3-phen-
oxybenzoylaminomethyl, N-phenylureido, phenylsulfonylaminomethyl, 9-fluorenyl-
methoxycarbonylaminomethyl, phenoxycarbonylaminomethyl, iso-butoxy-
carbonylamino, hydroxycarbonylmethyl or hydroxycarbonylmethoxy; and

R³ is i-Pr, cyclohexyl or 1-methyl-1-propyl.

11. The compound of claim 10, wherein R¹ is n-Pr; and R² and R²² together
form unsubstituted propylene.

12. The compound of claim 7, wherein:

R⁴ is alkyl, heteroaralkyl or aralkyl;

R⁵ is alkyl;

R⁶ is alkyl; and

Rⁿ is alkyl, alkoxy, heteroaryl, aryl or aralkyl.

13. The compound of claim 7, wherein:

R⁴ is i-Pr;

R⁵ and R⁶ are CH₂CH₂COOH; and

Rⁿ is methyl.

14. The compound of claim 2, wherein:

R² is CH₂CH₂SMe, C(OH)Me, CH₂CH₂S(O)Me, phenyl or CH₂C(O)NH₂;

R³ is hydroxymethyl, hydroxycarbonylmethyl or 4-imidazolylmethyl;

R⁴ is 4-hydroxyphenylmethyl;

R⁵ is hydroxymethyl; and

R¹ is H.

15. The compound of claim 6, wherein:

R² is H, alkyl or aryl;

R^3 is alkyl or heteroaralkyl;

R^4 is aralkyl;

R^5 is alkyl; and

R^1 is H, alkyl or aralkyl.

5 16. The compound of claim 6, wherein:

R^2 is $\text{CH}_2\text{CH}_2\text{SMe}$, $\text{C}(\text{OH})\text{Me}$, $\text{CH}_2\text{CH}_2\text{S}(\text{O})\text{Me}$, phenyl or $\text{CH}_2\text{C}(\text{O})\text{NH}_2$;

R^3 is hydroxymethyl, hydroxycarbonylmethyl or 4-imidazolylmethyl;

R^4 is 4-hydroxyphenylmethyl;

R^5 is hydroxymethyl; and

R^1 is H.

10 17. The compound of claim 1, wherein the compound is selected from the group consisting of:

AcEEVVPnV-(CO)-GMSYS-Am

AcEEVVPnV-CO-GMdSYS-Am

15 AcEEVVPnV-CO-GMdHYS-Am

AcEEVVPnV-CO-GMdDYS-Am

AcEEVVPnV-CO-GdMSYS-Am

AcEEVVPnV-CO-GdMdSYS-Am

AcEEVVPnV-CO-GdMHYS-Am

20 AcEEVVPnV-CO-GdMDYS-Am

AcEEVVPnV-CO-GdMdDYS-Am

AcEEVVPnV-CO-GGSYS-Am

AcEEVVPnV-CO-GGHYS-Am

AcEEVVPnV-CO-GGdHYS-Am

25 AcEEVVPnV-CO-GGDYS-Am

AcEEVVPnV-CO-GGdDYS-Am

AcEEVVPnV-CO-GQSYS-Am

AcEEVVPnV-CO-GQdSYS-Am

AcEEVVPnV-CO-GQdHYS-Am

30 AcEEVVPnV-CO-GQdDYS-Am

090914 071001

AcEEVVPnV-CO-GdQSYS-Am
AcEEVVPnV-CO-GdQdSYS-Am
AcEEVVPnV-CO-GdQHYS-Am
AcEEVVPnV-CO-GdQDYS-Am
AcEEVVPnV-CO-GdQdDYS-Am
AcEEVVPnV-CO-GTSYS-Am
AcEEVVPnV-CO-GTdSYS-Am
AcEEVVPnV-CO-GTHYS-Am
AcEEVVPnV-CO-GTDYS-Am
AcEEVVPnV-CO-GTdDYS-Am
AcEEVVPnV-CO-GSdSYS-Am
AcEEVVPnV-CO-GSdHYS-Am
AcEEVVPnV-CO-GSdDYS-Am
AcEEVVPnV-CO-GdSSYS-Am
AcEEVVPnV-CO-GdSdSYS-Am
AcEEVVPnV-CO-GdSHYS-Am
AcEEVVPnV-CO-GdSdHYS-Am
AcEEVVPnV-CO-GdSDYS-Am
AcEEVVPnV-CO-GdSdDYS-Am
AcEEVVPnV-CO-GM(O)HYS-Am
AcEEVVPnV-(CO)-GdM(O)SYS-Am
AcEEVVPnV-CO-GdM(O)dHYS-Am
AcEEVVPnV-CO-GdM(O)DYS-Am
AcEEVVPnV-CO-GdM(O)dDYS-Am
Ac-EEVVP-V-(CO)-GMSYS-Am
Ac-EEVVP-L-(CO)-GMSYS-Am
Ac-EEVVP-nL-(CO)-GMSYS-Am
Ac-EEVVP-Abu-(CO)-GMSYS-Am
Ac-EEVVP-(s,s)alloT-(CO)-GMSYS-Am
Ac-EEVVP-G(propynyl)-(CO)-GMSYS-Am

18. The compound of claim 1, wherein the compound is selected from the group consisting of:

AcEEVVPnV-CO-GdMDYS-Am

AcEEVVPnV-CO-GdMdDYS-Am

5 AcEEVVPnV-CO-GGSYS-Am

AcEEVVPnV-CO-GGHYS-Am

AcEEVVPnV-CO-GGDYS-Am

AcEEVVPnV-CO-GGdDYS-Am

AcEEVVPnV-CO-GQSYS-Am

10 AcEEVVPnV-CO-GQdSYS-Am

AcEEVVPnV-CO-GQdHYS-Am

AcEEVVPnV-CO-GQdDYS-Am

AcEEVVPnV-CO-GdQSYS-Am

AcEEVVPnV-CO-GdQdSYS-Am

15 AcEEVVPnV-CO-GdQHYS-Am

AcEEVVPnV-CO-GdQDYS-Am

AcEEVVPnV-CO-GdQdDYS-Am

AcEEVVPnV-CO-GTSYS-Am

AcEEVVPnV-CO-GTdSYS-Am

20 AcEEVVPnV-CO-GTHYS-Am

AcEEVVPnV-CO-GTDYS-Am

AcEEVVPnV-CO-GTdDYS-Am

AcEEVVPnV-CO-GSdSYS-Am

AcEEVVPnV-CO-GSdHYS-Am

25 AcEEVVPnV-CO-GSdDYS-Am

AcEEVVPnV-CO-GdSSYS-Am

AcEEVVPnV-CO-GdSdSYS-Am

AcEEVVPnV-CO-GdSHYS-Am

AcEEVVPnV-CO-GdSdHYS-Am

30 AcEEVVPnV-CO-GdSDYS-Am

AcEEVVPnV-CO-GdSdDYS-Am

AcEEVVPnV-CO-GM(O)HYS-Am

AcEEVVPnV-(CO)-GdM(O)SYS-Am

AcEEVVPnV-CO-GdM(O)DYS-Am

5 AcEEVVPnV-CO-GdM(O)dDYS-Am

Ac-EEVVP-(s,s)alloT-(CO)-GMSYS-Am

Ac-EEVVP-G(propynyl)-(CO)-GMSYS-Am

19. A pharmaceutical composition comprising as an active ingredient a compound of claim 1.

10 20. The pharmaceutical composition of claim 19 for use in treating disorders associated with Hepatitis C virus.

21. The pharmaceutical composition of claim 19 additionally comprising a pharmaceutically acceptable carrier.

15 22. The pharmaceutical composition of claim 21, additionally containing an antiviral agent.

23. The pharmaceutical composition of claim 22, still additionally containing an interferon.

24. The pharmaceutical composition of claim 23, wherein said antiviral agent is ribavirin and said interferon is α -interferon.

20 25. A method of treating disorders associated with the HCV protease, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which composition comprises therapeutically effective amounts of a compound of claim 1.

26. The method of claim 25, wherein said administration is subcutaneous.

25 27. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV protease.

28. A method of preparing a pharmaceutical composition for treating disorders associated with the HCV protease, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.

09909164 071901
106720 19160660

29. A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the group of compounds in claim 17.

5 30. A pharmaceutical composition for treating disorders associated with the HCV protease, said composition comprising therapeutically effective amount of one or more compounds in claim 17 and a pharmaceutically acceptable carrier.

0909164-071903